Akebia Therapeutics (AKBA)
(Delayed Data from NSDQ)
$1.42 USD
+0.11 (8.40%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $1.42 0.00 (0.00%) 6:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum B VGM
Brokerage Reports
Akebia Therapeutics, Inc. [AKBA]
Reports for Purchase
Showing records 61 - 80 ( 81 total )
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
2Q Review: Pending Merger Could Further Invigorate Auryxia Sales; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Keryx Merger Creates a Leading Renal Company; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
1Q18 Recap: Full Enrollment of Registration Studies on Track by Year End; Adjust PT to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
4Q Recap: Timeline Gap to Competitor Data Narrows; Yet Valuation Remains Compelling; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Program Updates Better Position Vadadustat for Commercial Success; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
3Q Recap: Shares Take a Hit Unfairly, Again; Two Vadadustat Readouts in 2H18; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
2Q Review; Vadadustat to Move FORWARD Into TRILOGY Soon; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
In Fresenius Deal, Akebia Fires First Commercial Shot Across the HIF Bow; Raise PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
1Q Recap: Phase 3 IDMC Says Steady as She Goes; Hyporesponders Trial Set to Start; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
European Partnership Provides Strong Economics, Removing Any Funding Concerns; Raise PT to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
4Q16 Recap: In the Face of Naysayers, Continued Disciplined Execution; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Patience Rewarded; Otsuka Deal Exceeds Expectations; Affirm Buy; Raise PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
ESA Hyporesponse Strongly Associated With Higher Mortality; New Study to Start in 4Q
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Akebia Initiates INNOVATE Ahead of EU Partnership, But Be Patient, a Deal Is Coming; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
1Q16 Recap: INNOVATE Program in Dialysis Patients Set to Start in 3Q16; Lower PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Focused on Signing EU Partner to Fund INNOVATE; Affirm Buy and Lower PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
EPO Revokes FibroGen''s ''823 Patent, Clearing Path for Vadadustat EU Partnership; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Licensing Deal with Mitsubishi Tanabe Brings Both Validation and Economics; Raise PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E